Answers are grounded in this paper and cite their sources.
The articular cartilage lacks blood vessels, nerves and lymphatic vessels. If damaged, it is difficult to achieve effective endogenous repair. Focal defects often progress to osteoarthritis. Traditional treatments such as microfracture surgery and autologous chondrocyte transplantation can alleviate related symptoms, but the repaired tissues are mostly fibrocartilage, which has a gap in mechanical performance compared to natural transparent cartilage. Moreover, they may face issues such as secondary surgeries, donor site damage, and insufficient long-term durability. Stem cells, due to their proliferative potential, multi-directional differentiation ability and microenvironmental regulatory function, are currently an important research direction for cartilage regeneration. This article systematically reviews the research progress of different stem cells in joint cartilage repair and summarizes related mechanisms such as directed differentiation, paracrine regulation, immune regulation and anti-apoptosis protection. In terms of clinical evidence-based application, data on mesenchymal stem cells (MSCs) is the most sufficient, which can improve pain, function and cartilage volume; iPSCs-derived cartilage shows advantages in long-term matrix synthesis and anti-hypertrophic apoptosis. However, heterogeneity of efficacy, lack of efficacy indicators, uncertain regulatory pathways, bottlenecks in manufacturing scale-up and problems of graft integration and durability still restrict clinical translation. Further exploration is still needed in the future.
No takes yet. Share an insight, caveat, or question.
Ningyu Tang (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: